66 results on '"Verreault M"'
Search Results
2. New hints towards a precision medicine strategy for IDH wild-type glioblastoma
- Author
-
White, K., Connor, K., Clerkin, J., Murphy, B.M., Salvucci, M., O'Farrell, A.C., Rehm, M., O'Brien, D., Prehn, J.H.M., Niclou, S.P., Lamfers, M.L.M., Verreault, M., Idbaih, A., Verhaak, R., Golebiewska, A., and Byrne, A.T.
- Published
- 2020
- Full Text
- View/download PDF
3. Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy
- Author
-
White, K., primary, Connor, K., additional, Meylan, M., additional, Bougoüin, A., additional, Salvucci, M., additional, Bielle, F., additional, O’Farrell, A.C., additional, Sweeney, K., additional, Weng, L., additional, Bergers, G., additional, Dicker, P., additional, Ashley, D.M., additional, Lipp, E.S., additional, Low, J.T., additional, Zhao, J., additional, Wen, P., additional, Prins, R., additional, Verreault, M., additional, Idbaih, A., additional, Biswas, A., additional, Prehn, J.H.M., additional, Lambrechts, D., additional, Arijs, I., additional, Lodi, F., additional, Dilcan, G., additional, Lamfers, M., additional, Leenstra, S., additional, Fabro, F., additional, Ntafoulis, I., additional, Kros, J.M., additional, Cryan, J., additional, Brett, F., additional, Quissac, E., additional, Beausang, A., additional, MacNally, S., additional, O’Halloran, P., additional, Clerkin, J., additional, Bacon, O., additional, Kremer, A., additional, Chi Yen, R.T., additional, Varn, F.S., additional, Verhaak, R.G.W., additional, Sautès-Fridman, C., additional, Fridman, W.H., additional, and Byrne, A.T., additional
- Published
- 2023
- Full Text
- View/download PDF
4. Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes:implications for precision immunotherapy
- Author
-
White, K., Connor, K., Meylan, M., Bougoüin, A., Salvucci, M., Bielle, F., O'Farrell, A. C., Sweeney, K., Weng, L., Bergers, G., Dicker, P., Ashley, D. M., Lipp, E. S., Low, J. T., Zhao, J., Wen, P., Prins, R., Verreault, M., Idbaih, A., Biswas, A., Prehn, J. H.M., Lambrechts, D., Arijs, I., Lodi, F., Dilcan, G., Lamfers, M., Leenstra, S., Fabro, F., Ntafoulis, I., Kros, J. M., Cryan, J., Brett, F., Quissac, E., Beausang, A., MacNally, S., O'Halloran, P., Clerkin, J., Bacon, O., Kremer, A., Chi Yen, R. T., Varn, F. S., Verhaak, R. G.W., Sautès-Fridman, C., Fridman, W. H., Byrne, A. T., White, K., Connor, K., Meylan, M., Bougoüin, A., Salvucci, M., Bielle, F., O'Farrell, A. C., Sweeney, K., Weng, L., Bergers, G., Dicker, P., Ashley, D. M., Lipp, E. S., Low, J. T., Zhao, J., Wen, P., Prins, R., Verreault, M., Idbaih, A., Biswas, A., Prehn, J. H.M., Lambrechts, D., Arijs, I., Lodi, F., Dilcan, G., Lamfers, M., Leenstra, S., Fabro, F., Ntafoulis, I., Kros, J. M., Cryan, J., Brett, F., Quissac, E., Beausang, A., MacNally, S., O'Halloran, P., Clerkin, J., Bacon, O., Kremer, A., Chi Yen, R. T., Varn, F. S., Verhaak, R. G.W., Sautès-Fridman, C., Fridman, W. H., and Byrne, A. T.
- Abstract
Background: New precision medicine therapies are urgently required for glioblastoma (GBM). However, to date, efforts to subtype patients based on molecular profiles have failed to direct treatment strategies. We hypothesised that interrogation of the GBM tumour microenvironment (TME) and identification of novel TME-specific subtypes could inform new precision immunotherapy treatment strategies. Materials and methods: A refined and validated microenvironment cell population (MCP) counter method was applied to >800 GBM patient tumours (GBM-MCP-counter). Specifically, partition around medoids (PAM) clustering of GBM-MCP-counter scores in the GLIOTRAIN discovery cohort identified three novel patient clusters, uniquely characterised by TME composition, functional orientation markers and immune checkpoint proteins. Validation was carried out in three independent GBM-RNA-seq datasets. Neoantigen, mutational and gene ontology analysis identified mutations and uniquely altered pathways across subtypes. The longitudinal Glioma Longitudinal AnalySiS (GLASS) cohort and three immunotherapy clinical trial cohorts [treatment with neoadjuvant/adjuvant anti-programmed cell death protein 1 (PD-1) or PSVRIPO] were further interrogated to assess subtype alterations between primary and recurrent tumours and to assess the utility of TME classifiers as immunotherapy biomarkers. Results: TMEHigh tumours (30%) displayed elevated lymphocyte, myeloid cell immune checkpoint, programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 transcripts. TMEHigh/mesenchymal+ patients featured tertiary lymphoid structures. TMEMed (46%) tumours were enriched for endothelial cell gene expression profiles and displayed heterogeneous immune populations. TMELow (24%) tumours were manifest as an ‘immune-desert’ group. TME subtype transitions upon recurrence were identified in the longitudinal GLASS cohort. Assessment of GBM immunoth
- Published
- 2023
5. Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma
- Author
-
Verreault, M., Wehbe, M., Strutt, D., Masin, D., Anantha, M., Walker, D., Chu, F., Backstrom, I., Kalra, J., Waterhouse, D., Yapp, D.T., and Bally, M.B.
- Published
- 2015
- Full Text
- View/download PDF
6. P10.17.B Androgen receptor signalling has independent prognostic value and is associated with resistance to temozolomide and tumour growth in glioblastoma
- Author
-
Birzu, C, primary, Boussier, J, additional, Belin, L, additional, Da Costa Pereira, T, additional, Quissac, E, additional, Zerara, M, additional, Lemaire, N, additional, Mokhtari, K, additional, Verreault, M, additional, and Idbaih, A, additional
- Published
- 2022
- Full Text
- View/download PDF
7. 292P Androgen receptor signalling is associated with resistance to temozolomide and tumour growth in glioblastoma
- Author
-
Birzu, C., primary, Boussier, J., additional, Belin, L., additional, Lemaire, N., additional, Da Costa Pereira, T., additional, Mokhtari, K., additional, Verreault, M., additional, and Idbaih, A., additional
- Published
- 2022
- Full Text
- View/download PDF
8. P13.11 Transcriptional CDK inhibitors, CYC065 and THZ1 promote apoptosis in preclinical models of primary and recurrent GBM tumour cells and glioma stem cells
- Author
-
Juric, V, primary, Duessmann, H, additional, Jahns, H, additional, Verreault, M, additional, Idbaih, A, additional, Lamfers, M L, additional, Hopkins, A M, additional, Prehn, J H, additional, Rehm, M, additional, and Murphy, B M, additional
- Published
- 2021
- Full Text
- View/download PDF
9. New hints towards a precision medicine strategy for IDH wild-type glioblastoma
- Author
-
White, K. (Kirsten), Connor, K., Clerkin, J., Murphy, B.M., Salvucci, M., O'Farrell, A.C., Rehm, M., O'Brien, D., Prehn, J.H.M., Niclou, S.P., Lamfers, M.L.M. (Martine), Verreault, M., Idbaih, A. (Ahmed), Verhaak, R.G.W. (Roel), Golebiewska, A., Byrne, A.T., White, K. (Kirsten), Connor, K., Clerkin, J., Murphy, B.M., Salvucci, M., O'Farrell, A.C., Rehm, M., O'Brien, D., Prehn, J.H.M., Niclou, S.P., Lamfers, M.L.M. (Martine), Verreault, M., Idbaih, A. (Ahmed), Verhaak, R.G.W. (Roel), Golebiewska, A., and Byrne, A.T.
- Published
- 2020
- Full Text
- View/download PDF
10. New hints towards a precision medicine strategy for IDH wild-type glioblastoma
- Author
-
White, K, Connor, K, Clerkin, J, Murphy, BM, Salvucci, M, O'Farrell, AC, Rehm, M, O'Brien, D, Prehn, JHM, Niclou, SP, Lamfers, Martine, Verreault, M, Idbaih, A, Verhaak, RGW, Golebiewska, A, Byrne, AT, White, K, Connor, K, Clerkin, J, Murphy, BM, Salvucci, M, O'Farrell, AC, Rehm, M, O'Brien, D, Prehn, JHM, Niclou, SP, Lamfers, Martine, Verreault, M, Idbaih, A, Verhaak, RGW, Golebiewska, A, and Byrne, AT
- Published
- 2020
11. Bile acids self-stimulate their own glucuronidation through a PXR-dependent mechanism
- Author
-
Verreault, M., primary, Trottier, J., additional, Wunsch, E., additional, Milkiewicz, P., additional, and Barbier, O., additional
- Published
- 2017
- Full Text
- View/download PDF
12. ET-62 * HIGHLY SELECTIVE ACTIVITY OF MDM2 INHIBITOR RG7112 AGAINST MDM2-AMPLIFIED/TP53 WILD-TYPE GLIOBLASTOMAS
- Author
-
Verreault, M., primary, Levasseur, C., additional, Schmitt, C., additional, Guehennec, J., additional, Labussiere, M., additional, Marie, Y., additional, Haidar, S., additional, Mokhtari, K., additional, Hoang-Xuan, K., additional, Sanson, M., additional, Ligon, K., additional, Delattre, J.-Y., additional, and Idbaih, A., additional
- Published
- 2014
- Full Text
- View/download PDF
13. Diffuse midline glioma invasion and metastasis rely on cell-autonomous signaling.
- Author
-
Bruschi M, Midjek L, Ajlil Y, Vairy S, Lancien M, Ghermaoui S, Kergrohen T, Verreault M, Idbaih A, de Biagi CAO Junior, Liu I, Filbin MG, Beccaria K, Blauwblomme T, Puget S, Tauziede-Espariat A, Varlet P, Dangouloff-Ros V, Boddaert N, Le Teuff G, Grill J, Montagnac G, Elkhatib N, Debily MA, and Castel D
- Subjects
- Child, Humans, Signal Transduction, Tumor Microenvironment, Brain Neoplasms pathology, Glioma pathology
- Abstract
Background: Diffuse midline gliomas (DMG) are pediatric tumors with negligible 2-year survival after diagnosis characterized by their ability to infiltrate the central nervous system. In the hope of controlling the local growth and slowing the disease, all patients receive radiotherapy. However, distant progression occurs frequently in DMG patients. Current clues as to what causes tumor infiltration circle mainly around the tumor microenvironment, but there are currently no known determinants to predict the degree of invasiveness., Methods: In this study, we use patient-derived glioma stem cells (GSCs) to create patient-specific 3D avatars to model interindividual invasion and elucidate the cellular supporting mechanisms., Results: We show that GSC models in 3D mirror the invasive behavior of the parental tumors, thus proving the ability of DMG to infiltrate as an autonomous characteristic of tumor cells. Furthermore, we distinguished 2 modes of migration, mesenchymal and ameboid-like, and associated the ameboid-like modality with GSCs derived from the most invasive tumors. Using transcriptomics of both organoids and primary tumors, we further characterized the invasive ameboid-like tumors as oligodendrocyte progenitor-like, with highly contractile cytoskeleton and reduced adhesion ability driven by crucial over-expression of bone morphogenetic pathway 7 (BMP7). Finally, we deciphered MEK, ERK, and Rho/ROCK kinases activated downstream of the BMP7 stimulation as actionable targets controlling tumor cell motility., Conclusions: Our findings identify 2 new therapeutic avenues. First, patient-derived GSCs represent a predictive tool for patient stratification in order to adapt irradiation strategies. Second, autocrine and short-range BMP7-related signaling becomes a druggable target to prevent DMG spread and metastasis., (© The Author(s) 2023. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.)
- Published
- 2024
- Full Text
- View/download PDF
14. Genomic Exploration of Distinct Molecular Phenotypes Steering Temozolomide Resistance Development in Patient-Derived Glioblastoma Cells.
- Author
-
Fabro F, Kers TV, Feller KJ, Beerens C, Ntafoulis I, Idbaih A, Verreault M, Connor K, Biswas A, Salvucci M, Prehn JHM, Byrne AT, O'Farrell AC, Lambrechts D, Dilcan G, Lodi F, Arijs I, Kremer A, Tching Chi Yen R, Chien MP, Lamfers MLM, and Leenstra S
- Subjects
- Humans, Temozolomide pharmacology, Temozolomide therapeutic use, Dacarbazine pharmacology, Dacarbazine therapeutic use, Antineoplastic Agents, Alkylating pharmacology, Antineoplastic Agents, Alkylating therapeutic use, Cell Line, Tumor, Phenotype, Genomics, Drug Resistance, Neoplasm genetics, Gene Expression Regulation, Neoplastic, Glioblastoma drug therapy, Glioblastoma genetics, Glioblastoma metabolism, Brain Neoplasms drug therapy, Brain Neoplasms genetics, Brain Neoplasms metabolism
- Abstract
Chemotherapy using temozolomide is the standard treatment for patients with glioblastoma. Despite treatment, prognosis is still poor largely due to the emergence of temozolomide resistance. This resistance is closely linked to the widely recognized inter- and intra-tumoral heterogeneity in glioblastoma, although the underlying mechanisms are not yet fully understood. To induce temozolomide resistance, we subjected 21 patient-derived glioblastoma cell cultures to Temozolomide treatment for a period of up to 90 days. Prior to treatment, the cells' molecular characteristics were analyzed using bulk RNA sequencing. Additionally, we performed single-cell RNA sequencing on four of the cell cultures to track the evolution of temozolomide resistance. The induced temozolomide resistance was associated with two distinct phenotypic behaviors, classified as "adaptive" (ADA) or "non-adaptive" (N-ADA) to temozolomide. The ADA phenotype displayed neurodevelopmental and metabolic gene signatures, whereas the N-ADA phenotype expressed genes related to cell cycle regulation, DNA repair, and protein synthesis. Single-cell RNA sequencing revealed that in ADA cell cultures, one or more subpopulations emerged as dominant in the resistant samples, whereas N-ADA cell cultures remained relatively stable. The adaptability and heterogeneity of glioblastoma cells play pivotal roles in temozolomide treatment and contribute to the tumor's ability to survive. Depending on the tumor's adaptability potential, subpopulations with acquired resistance mechanisms may arise.
- Published
- 2023
- Full Text
- View/download PDF
15. Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers.
- Author
-
Ntafoulis I, Kleijn A, Ju J, Jimenez-Cowell K, Fabro F, Klein M, Chi Yen RT, Balvers RK, Li Y, Stubbs AP, Kers TV, Kros JM, Lawler SE, Beerepoot LV, Kremer A, Idbaih A, Verreault M, Byrne AT, O'Farrell AC, Connor K, Biswas A, Salvucci M, Prehn JHM, Lambrechts D, Dilcan G, Lodi F, Arijs I, van den Bent MJ, Dirven CMF, Leenstra S, and Lamfers MLM
- Subjects
- Humans, Temozolomide pharmacology, Temozolomide therapeutic use, Dacarbazine pharmacology, Dacarbazine therapeutic use, Drug Evaluation, Preclinical, Biomarkers, DNA therapeutic use, Drug Resistance, Neoplasm genetics, Antineoplastic Agents, Alkylating pharmacology, Antineoplastic Agents, Alkylating therapeutic use, Cell Line, Tumor, Tumor Microenvironment, Glioblastoma drug therapy, Glioblastoma genetics, Glioblastoma metabolism, Glioma, Brain Neoplasms drug therapy, Brain Neoplasms genetics, Brain Neoplasms metabolism
- Abstract
Background: Patient-derived glioma stem-like cells (GSCs) have become the gold-standard in neuro-oncological research; however, it remains to be established whether loss of in situ microenvironment affects the clinically-predictive value of this model. We implemented a GSC monolayer system to investigate in situ-in vitro molecular correspondence and the relationship between in vitro and patient response to temozolomide (TMZ)., Methods: DNA/RNA-sequencing was performed on 56 glioblastoma tissues and 19 derived GSC cultures. Sensitivity to TMZ was screened across 66 GSC cultures. Viability readouts were related to clinical parameters of corresponding patients and whole-transcriptome data., Results: Tumour DNA and RNA sequences revealed strong similarity to corresponding GSCs despite loss of neuronal and immune interactions. In vitro TMZ screening yielded three response categories which significantly correlated with patient survival, therewith providing more specific prediction than the binary MGMT marker. Transcriptome analysis identified 121 genes related to TMZ sensitivity of which 21were validated in external datasets., Conclusion: GSCs retain patient-unique hallmark gene expressions despite loss of their natural environment. Drug screening using GSCs predicted patient response to TMZ more specifically than MGMT status, while transcriptome analysis identified potential biomarkers for this response. GSC drug screening therefore provides a tool to improve drug development and precision medicine for glioblastoma., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
16. Synthesis of Bleomycin-Inspired RNA Ligands Targeting the Biogenesis of Oncogenic miRNAs.
- Author
-
Maucort C, Bonnet M, Ortuno JC, Tucker G, Quissac E, Verreault M, Azoulay S, Di Giorgio C, Di Giorgio A, and Duca M
- Subjects
- Humans, Bleomycin, Ligands, Structure-Activity Relationship, MicroRNAs metabolism, Neoplasms drug therapy
- Abstract
Noncoding RNAs (ncRNAs) play pivotal roles in the regulation of gene expression and represent a promising target for the development of new therapeutic approaches. Among these ncRNAs, microRNAs (miRNAs or miRs) are involved in the regulation of gene expression, and their dysregulation has been linked to several diseases such as cancers. Indeed, oncogenic miRNAs are overexpressed in cancer cells, thus promoting tumorigenesis and maintenance of cancer stem cells that are resistant to chemotherapy and often responsible for therapeutic failure. Here, we describe the design and synthesis of new small-molecule RNA binders able to inhibit the biogenesis of oncogenic miRNAs and target efficiently cancer stem cells. Through the biochemical study of their interaction with the target and thanks to intracellular assays, we describe the structure-activity relationships for this new series of RNA ligands, and we identify compounds bearing a very promising antiproliferative activity against cancer stem cells.
- Published
- 2023
- Full Text
- View/download PDF
17. Challenges in glioblastoma research: focus on the tumor microenvironment: (Trends in Cancer, 9:1 p:9-27, 2023).
- Author
-
Bikfalvi A, da Costa CA, Avril T, Barnier JV, Bauchet L, Brisson L, Cartron PF, Castel H, Chevet E, Chneiweiss H, Clavreul A, Constantin B, Coronas V, Daubon T, Dontenwill M, Ducray F, Entz-Werlé N, Figarella-Branger D, Fournier I, Frenel JS, Gabut M, Galli T, Gavard J, Huberfeld G, Hugnot JP, Idbaih A, Junier MP, Mathivet T, Menei P, Meyronet D, Mirjolet C, Morin F, Mosser J, Moyal EC, Rousseau V, Salzet M, Sanson M, Seano G, Tabouret E, Tchoghandjian A, Turchi L, Vallette FM, Vats S, Verreault M, and Virolle T
- Published
- 2023
- Full Text
- View/download PDF
18. Comparative analysis of deeply phenotyped GBM cohorts of 'short-term' and 'long-term' survivors.
- Author
-
Biswas A, Salvucci M, Connor K, Düssmann H, Carberry S, Fichtner M, King E, Murphy B, O'Farrell AC, Cryan J, Beausang A, Heffernan J, Cremona M, Hennessy BT, Clerkin J, Sweeney KJ, MacNally S, Brett F, O'Halloran P, Bacon O, Furney S, Verreault M, Quissac E, Bielle F, Ahmed MH, Idbaih A, Leenstra S, Ntafoulis I, Fabro F, Lamfers M, Golebiewska A, Hertel F, Niclou SP, Yen RTC, Kremer A, Dilcan G, Lodi F, Arijs I, Lambrechts D, Purushothama MK, Kel A, Byrne AT, and Prehn JHM
- Subjects
- Humans, Aged, Prognosis, Brain pathology, Survivors, Glioblastoma pathology, Brain Neoplasms pathology
- Abstract
Background: Glioblastoma (GBM) is an aggressive brain cancer that typically results in death in the first 15 months after diagnosis. There have been limited advances in finding new treatments for GBM. In this study, we investigated molecular differences between patients with extremely short (≤ 9 months, Short term survivors, STS) and long survival (≥ 36 months, Long term survivors, LTS)., Methods: Patients were selected from an in-house cohort (GLIOTRAIN-cohort), using defined inclusion criteria (Karnofsky score > 70; age < 70 years old; Stupp protocol as first line treatment, IDH wild type), and a multi-omic analysis of LTS and STS GBM samples was performed., Results: Transcriptomic analysis of tumour samples identified cilium gene signatures as enriched in LTS. Moreover, Immunohistochemical analysis confirmed the presence of cilia in the tumours of LTS. Notably, reverse phase protein array analysis (RPPA) demonstrated increased phosphorylated GAB1 (Y627), SRC (Y527), BCL2 (S70) and RAF (S338) protein expression in STS compared to LTS. Next, we identified 25 unique master regulators (MR) and 13 transcription factors (TFs) belonging to ontologies of integrin signalling and cell cycle to be upregulated in STS., Conclusion: Overall, comparison of STS and LTS GBM patients, identifies novel biomarkers and potential actionable therapeutic targets for the management of GBM., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
19. Oxazolo[5,4-f]quinoxaline-type selective inhibitors of glycogen synthase kinase-3α (GSK-3α): Development and impact on temozolomide treatment of glioblastoma cells.
- Author
-
Hasyeoui M, Lassagne F, Erb W, Nael M, Elokely KM, Chaikuad A, Knapp S, Jorda A, Vallés SL, Quissac E, Verreault M, Robert T, Bach S, Samarat A, and Mongin F
- Subjects
- Humans, Temozolomide, Glycogen Synthase Kinase 3 beta, Quinoxalines pharmacology, Protein Serine-Threonine Kinases, Protein Isoforms, Glycogen Synthase Kinase 3, Glioblastoma
- Abstract
The 2-(3-pyridyl)oxazolo[5,4-f]quinoxalines CD-07 and FL-291 are ATP-competitive GSK-3 kinase inhibitors. Here, we investigated the impact of FL-291 on neuroblastoma cell viability and showed that treatment at 10 μM (i.e. ∼500 times the IC
50 against the GSK-3 isoforms) has no significant effect on the viability of NSC-34 motoneuron-like cells. A study performed on primary neurons (non-cancer cells) led to similar results. The structures co-crystallized with GSK-3β revealed similar binding modes for FL-291 and CD-07, with their hinge-oriented planar tricyclic system. Both GSK isoforms show the same orientations for the amino acids at the binding pocket except for Phe130 (α) and Phe67 (β), leading to a larger pocket on the opposite side of the hinge region for the α isoform. Calculations of the thermodynamic properties of the binding pockets highlighted the required features of potential ligands; these should have a hydrophobic core (which could be larger in the case of GSK-3β) surrounded by polar areas (a little more polar in the case of GSK-3α). A library of 27 analogs of FL-291 and CD-07 was thus designed and synthesized by taking advantage of this hypothesis. While the introduction of substituents at different positions of the pyridine ring, the replacement of the pyridine by other heterocyclic moieties, or the replacement of the quinoxaline ring by a quinoline moiety did not lead to any improvement, the replacement of the N-(thio)morpholino of FL-291/CD-07 by a slightly more polar N-thiazolidino led to a significant result. Indeed, the new inhibitor MH-124 showed clear selectivity for the α isoform, with IC50 values of 17 nM and 239 nM on GSK-3α and GSK-3β, respectively. Finally, the efficacy of MH-124 was evaluated on two glioblastoma cell lines. Although MH-124 alone did not have a significant impact on cell survival, its addition to temozolomide (TMZ) significantly reduced the TMZ IC50 values on the cells tested. The use of the Bliss model allowed a synergy to be evidenced at certain concentrations., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier Inc. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
20. Expression and Prognostic Value of CD80 and CD86 in the Tumor Microenvironment of Newly Diagnosed Glioblastoma.
- Author
-
Ahmed MH, Hernández-Verdin I, Bielle F, Verreault M, Lerond J, Alentorn A, Sanson M, and Idbaih A
- Subjects
- Humans, Prognosis, Retrospective Studies, Tumor Microenvironment, RNA, Messenger genetics, RNA, Messenger metabolism, Glioblastoma diagnosis, Glioblastoma genetics
- Abstract
Background: Strategies to modulate the tumor microenvironment (TME) have opened new therapeutic avenues with dramatic yet heterogeneous intertumoral efficacy in multiple cancers, including glioblastomas (GBMs). Therefore, investigating molecular actors of TME may help understand the interactions between tumor cells and TME. Immune checkpoint proteins such as a Cluster of Differentiation 80 (CD80) and CD86 are expressed on the surface of tumor cells and infiltrative tumor lymphocytes. However, their expression and prognostic value in GBM microenvironment are still unclear., Methods: In this study, we investigated, in a retrospective local discovery cohort and a validation TCGA dataset, expression of CD80 and CD86 at mRNA level and their prognostic significance in response to standard of care. Furthermore, CD80 and CD86 at the protein level were investigated in the discovery cohort., Results: Both CD80 and CD86 are expressed heterogeneously in the TME at mRNA and protein levels. In a univariate analysis, the mRNA expression of CD80 and CD86 was not significantly correlated with OS in both local OncoNeuroTek dataset and TCGA datasets. CD80 and CD86 mRNA high expression was significantly associated with shorter progression free survival (PFS) ( p < 0.05). These findings were validated using the TCGA cohort; higher CD80 and CD86 expressions were correlated with shorter PFS ( p < 0.05). In multivariate analysis, CD86 mRNA expression was an independent prognostic factor for PFS in the TCGA dataset only ( p < 0.05)., Conclusion: CD86 could be used as a potential biomarker for the prognosis of GBM patients treated with immunotherapy; however, additional studies are needed to validate these findings.
- Published
- 2023
- Full Text
- View/download PDF
21. Low-Intensity Pulsed Ultrasound-Mediated Blood-Brain Barrier Opening Increases Anti-Programmed Death-Ligand 1 Delivery and Efficacy in Gl261 Mouse Model.
- Author
-
Ahmed MH, Hernández-Verdin I, Quissac E, Lemaire N, Guerin C, Guyonnet L, Zahr N, Mouton L, Santin M, Petiet A, Schmitt C, Bouchoux G, Canney M, Sanson M, Verreault M, Carpentier A, and Idbaih A
- Abstract
Therapeutic antibodies targeting immune checkpoints have shown limited efficacy in clinical trials in glioblastoma (GBM) patients. Ultrasound-mediated blood-brain barrier opening (UMBO) using low-intensity pulsed ultrasound improved drug delivery to the brain. We explored the safety and the efficacy of UMBO plus immune checkpoint inhibitors in preclinical models of GBM. A blood-brain barrier (BBB) opening was performed using a 1 MHz preclinical ultrasound system in combination with 10 µL/g microbubbles. Brain penetration of immune checkpoint inhibitors was determined, and immune cell populations were evaluated using flow cytometry. The impact of repeated treatments on survival was determined. In syngeneic GL261-bearing immunocompetent mice, we showed that UMBO safely and repeatedly opened the BBB. BBB opening was confirmed visually and microscopically using Evans blue dye and magnetic resonance imaging. UMBO plus anti-PDL-1 was associated with a significant improvement of overall survival compared to anti-PD-L1 alone. Using mass spectroscopy, we showed that the penetration of therapeutic antibodies can be increased when delivered intravenously compared to non-sonicated brains. Furthermore, we observed an enhancement of activated microglia percentage when combined with anti-PD-L1. Here, we report that the combination of UMBO and anti-PD-L1 dramatically increases GL261-bearing mice's survival compared to their counterparts treated with anti-PD-L1 alone. Our study highlights the BBB as a limitation to overcome in order to increase the efficacy of anti-PD-L1 in GBM and supports clinical trials combining UMBO and in GBM patients.
- Published
- 2023
- Full Text
- View/download PDF
22. Impact of Blueberry Consumption on the Human Fecal Bileacidome: A Pilot Study of Bile Acid Modulation by Freeze-Dried Blueberry.
- Author
-
Gagnon W, Garneau V, Trottier J, Verreault M, Couillard C, Roy D, Marette A, Drouin-Chartier JP, Vohl MC, and Barbier O
- Subjects
- Female, Humans, Male, Cholic Acid, Feces chemistry, Glucose analysis, Glycine, Pilot Projects, Powders, Bile Acids and Salts analysis, Blueberry Plants
- Abstract
Cholesterol-derived bile acids (BAs) affect numerous physiological functions such as glucose homeostasis, lipid metabolism and absorption, intestinal inflammation and immunity, as well as intestinal microbiota diversity. Diet influences the composition of the BA pool. In the present study, we analyzed the impact of a dietary supplementation with a freeze-dried blueberry powder (BBP) on the fecal BA pool composition. The diet of 11 men and 13 women at risk of metabolic syndrome was supplemented with 50 g/day of BBP for 8 weeks, and feces were harvested before (pre) and after (post) BBP consumption. BAs were profiled using liquid chromatography coupled with tandem mass spectrometry. No significant changes in total BAs were detected when comparing pre- vs. post-BBP consumption samples. However, post-BBP consumption samples exhibited significant accumulations of glycine-conjugated BAs ( p = 0.04), glycochenodeoxycholic ( p = 0.01), and glycoursodeoxycholic ( p = 0.01) acids, as well as a significant reduction ( p = 0.03) in the secondary BA levels compared with pre-BBP feces. In conclusion, the fecal bileacidome is significantly altered after the consumption of BBP for 8 weeks. While additional studies are needed to fully understand the underlying mechanisms and physiological implications of these changes, our data suggest that the consumption of blueberries can modulate toxic BA elimination.
- Published
- 2022
- Full Text
- View/download PDF
23. [Perpetrators and victims of intimate partner violence: Personological profiles of people with borderline personality disorder].
- Author
-
Savard C, Gamache D, Payant M, Gagné-Pomerleau É, Dompierre RC, Maranda J, Potvin O, Verreault M, Tremblay M, Roy D, and Villeneuve É
- Subjects
- Humans, Female, Male, Personality Disorders, Surveys and Questionnaires, Spouse Abuse psychology, Borderline Personality Disorder epidemiology, Intimate Partner Violence psychology
- Abstract
Objective Personality disorders and intimate partner violence (IPV) are two problems recognized as major public health issues associated with serious individual and societal repercussions. Several studies have documented the links between borderline personality disorder (BPD) and IPV; however, we know very little about the specific pathological traits contributing to IPV. The study aims to document the phenomenon of IPV committed and suffered in persons with BPD and to draw profiles from the personality facets of the DSM-5 Alternative Model for Personality Disorders (AMPD). Method One hundred and eight BPD participants (83.3% female; Mage = 32.39, SD = 9.00) referred to a day hospital program following a crisis episode completed a battery of questionnaires including the French versions of the Revised Conflict Tactics Scales, evaluating physical and psychological IPV committed and suffered, and the Personality Inventory for the DSM-5- Faceted Brief Form, evaluating 25 pathological facets of personality. Results Among the participants, 78.7% report having committed psychological IPV, while 68.5% have been victims, which is more than the estimates published by the World Health Organization (27%). In addition, 31.5% would have committed physical IPV, while 22.2% would have been victims. IPV appears to be bidirectional since 85.9% of participants who are perpetrators of psychological IPV also report suffering from it and 52.9% of participants who are perpetrators of physical IPV report being also victims. Nonparametric group comparisons indicate that Hostility, Suspiciousness, Duplicity, Risk-Taking, and Irresponsibility facets distinguish physically and psychologically violent participants from nonviolent participants. High results on Hostility, Callousness, Manipulation, and Risk-taking facets characterize participants who are victims of psychological IPV, while an elevation in Hostility, Withdrawal, Avoidance of intimacy, and Risk-taking facets and a low result on the Submission facet distinguish participants who are victims of physical IPV from non-victims. Regression analyzes show that the Hostility facet alone explains a significant variance in the results of IPV perpetrated, while the Irresponsibility facet contributes substantially to the variance of the results of IPV experienced. Conclusion Results show the high prevalence of IPV in a sample of persons with BPD, as well as its bidirectional nature. Beyond the diagnosis of BPD, certain specific facets of the personality (including Hostility and Irresponsability) make it possible to target persons at greater risk of committing and suffering from psychological and physical IPV.
- Published
- 2022
24. [Psychotherapy prognostic factors for personality disorders (PD) treatment: The role of self-reported questionnaires].
- Author
-
Boivin N, Gill LP, Martin-Zément I, Provencher MÈ, Dompierre RC, Maranda J, Verreault M, Villeneuve É, Gamache D, and Savard C
- Subjects
- Humans, Self Report, Retrospective Studies, Prognosis, Surveys and Questionnaires, Personality Disorders therapy, Personality Disorders diagnosis, Psychotherapy
- Abstract
Objectives Dropout rates in psychotherapy are known to be high in patients with personality disorders (PD; ranging from 25% and 64% for Borderline PD). Faced with this observation, the Treatment Attrition-Retention Scale for Personality Disorders (TARS-PD; Gamache et coll., 2017) was developed to precisely identify patients with PD at high risk of abandoning therapy based on 15 criteria, regrouped in 5 factors: Pathological Narcissism, Antisocial/Psychopathy, Secondary Gain, Low Motivation, and Cluster A Features. However, we have limited knowledge about the relevance of self-reported questionnaires commonly used with PD patients to establish treatment prognosis. Thus, the purpose of this study is to evaluate the link between such questionnaires and the five factors of the TARS-PD. Method Data was retrospectively retrieved from the clinical files of 174 participants with a PD (including 56% with borderline traits or PD), who were evaluated at the Centre de traitement le Faubourg Saint-Jean and completed the French version of the following questionnaires: Borderline Symptom List (BSL-23), Brief Version of the Pathological Narcissism Inventory (B-PNI), Interpersonal Reactivity Index (IRI), Buss-Perry Aggression Questionnaire (BPAQ), Barratt Impulsiveness Scale (BIS-11), Social Functioning Questionnaire (SFQ), Self and Interpersonal Functioning Scale (SIFS) and Personality Inventory for DSM-5- Faceted Brief Form (PID-5-FBF). The TARS-PD was completed by well-trained psychologists specialized in PD treatment. Descriptive analyses and regression between self-reported questionnaires and the five factors of the TARS-PD as well as its total score were performed to determine which variables from the self-reported questionnaires completed by the individuals contribute most strongly to the statistical prediction of the variables of the TARS-PD rated by the clinicians. Results The subscales that significantly contribute to the Pathological Narcissism factor (adjusted R2=0,12) are: Empathy (SIFS), Impulsivity (negatively; PID-5), and Entitlement Rage (B-PNI). The subscales associated with the Antisociality/Psychopathy factor (adjusted R2=0,24) are Manipulativeness, Submissiveness (negatively), and Callousness from the PID-5, and Empathic Concern (IRI). The scales contributing substantially to the Secondary gains factor (adjusted R2=0,20) are Frequency (SFQ), Anger (negatively; BPAQ), Fantasy (negatively) and Empathic Concern (IRI), Rigid Perfectionism (negatively) and Unusual Beliefs and Experiences (PID-5). Low motivation (adjusted R2=0,10) is significantly explained by Total BSL score (negatively) and Satisfaction (SFQ) subscale. Finally, the subscales significantly associated to Cluster A features (adjusted R2=0,09) are Intimacy (SIFS) and Submissiveness (negatively, PID-5). Conclusion Some scales from self-reported questionnaires demonstrated modest but significant associations with TARS-PD factors. Those scales might be useful in the scoring of the TARS-PD and provide additional information for patients' clinical orientation.
- Published
- 2022
25. [Validation of a screening procedure for borderline personality disorder based on the Alternative DSM-5 Model for Personality Disorders].
- Author
-
Gamache D, Savard C, Payant M, Leclerc P, Dompierre RC, Roy D, Tremblay M, Verreault M, and Villeneuve É
- Subjects
- Humans, Diagnostic and Statistical Manual of Mental Disorders, Personality Disorders diagnosis, Personality, Surveys and Questionnaires, Borderline Personality Disorder diagnosis
- Abstract
Objectives The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) includes an Alternative Model for Personality Disorders (DSM-5), which defines personality disorders based on two dimensional criteria. Criterion A corresponds to the severity of personality dysfunction in the areas of self and interpersonal functioning, while Criterion B comprises five pathological domains including a total of 25 facets. Six specific disorders, including borderline personality disorder (BPD), are defined in the AMPD based on Criteria A and B. However, there is currently very little data on these diagnoses as they are operationalized in the MATP. This study aims to present data on this recent operationalization of BPD. More specifically, we will first introduce a procedure, based on self-reported questionnaires covering the two main MATP criteria, implemented to generate the BPD diagnosis from the AMPD. Then, we will assess its validity (a) by documenting its prevalence in a clinical sample; (b) by determining its degree of correspondence with the "traditional" BPD categorical diagnosis and with a dimensional measure of borderline symptomatology; (c) by presenting convergent validity data with constructs relevant to the study of BPD (impulsivity, aggression); and (d) by determining the incremental validity of the proposed procedure in contrast with a simplified approach where only Criterion B would be considered. Method Data from 287 patients recruited as part of the admission process at the Centre de traitement le Faubourg Saint-Jean of the CIUSSS-Capitale-Nationale were analyzed. The BPD diagnosis from the MATP was generated based on two validated self-report questionnaires, in their French version, namely the Self and Interpersonal Functioning Scale (Criterion A) and the Personality Inventory for DSM-5-Faceted Brief Form (Criterion B). Results The BPD diagnosis, as operationalized in the AMPD, had a prevalence of 39.7% in the sample. A moderate fit with the clinician's diagnosis of BPD according to the traditional DSM-5 categorical model was observed, as well as a strong correlation with a dimensional measure of borderline symptomatology. Nomological network analysis revealed high and theoretically expected correlations between the disorder and measures of aggression and impulsivity. The proposed diagnostic extraction procedure, which uses Criteria A and B, showed incremental validity in the statistical prediction of external variables (borderline symptomatology, aggression, impulsivity) compared to a simplified procedure using only Criterion B. Conclusions The proposed procedure for generating the BPD diagnosis according to the MATP definition yields promising results and could allow screening for the disorder based on this contemporary conceptualization of personality pathologies.
- Published
- 2022
26. Identification of growth hormone receptor as a relevant target for precision medicine in low-EGFR expressing glioblastoma.
- Author
-
Verreault M, Segoviano Vilchis I, Rosenberg S, Lemaire N, Schmitt C, Guehennec J, Royer-Perron L, Thomas JL, Lam TT, Dingli F, Loew D, Ducray F, Paris S, Carpentier C, Marie Y, Laigle-Donadey F, Rousseau A, Pigat N, Boutillon F, Bielle F, Mokhtari K, Frank SJ, de Reyniès A, Hoang-Xuan K, Sanson M, Goffin V, and Idbaih A
- Subjects
- Cell Line, Tumor, ErbB Receptors genetics, ErbB Receptors metabolism, Humans, Precision Medicine, Receptors, Somatotropin genetics, Receptors, Somatotropin therapeutic use, Brain Neoplasms drug therapy, Brain Neoplasms genetics, Brain Neoplasms metabolism, Glioblastoma drug therapy, Glioblastoma genetics, Glioblastoma metabolism
- Abstract
Objective: New therapeutic approaches are needed to improve the prognosis of glioblastoma (GBM) patients., Methods: With the objective of identifying alternative oncogenic mechanisms to abnormally activated epidermal growth factor receptor (EGFR) signalling, one of the most common oncogenic mechanisms in GBM, we performed a comparative analysis of gene expression profiles in a series of 54 human GBM samples. We then conducted gain of function as well as genetic and pharmocological inhibition assays in GBM patient-derived cell lines to functionnally validate our finding., Results: We identified that growth hormone receptor (GHR) signalling defines a distinct molecular subset of GBMs devoid of EGFR overexpression. GHR overexpression was detected in one third of patients and was associated with low levels of suppressor of cytokine signalling 2 (SOCS2) expression due to SOCS2 promoter hypermethylation. In GBM patient-derived cell lines, GHR signalling modulates the expression of proteins involved in cellular movement, promotes cell migration, invasion and proliferation in vitro and promotes tumourigenesis, tumour growth, and tumour invasion in vivo. GHR genetic and pharmacological inhibition reduced cell proliferation and migration in vitro., Conclusion: This study pioneers a new field of investigation to improve the prognosis of GBM patients., (© 2022 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.)
- Published
- 2022
- Full Text
- View/download PDF
27. Androgen Glucuronidation in Mice: When, Where, and How.
- Author
-
Grosse L, Chouinard S, Pâquet S, Verreault M, Trottier J, Bélanger A, and Barbier O
- Abstract
Glucuronidation, catalyzed by UDP-glucuronosyltransferase UGT2B enzymes, is a major inactivating and elimination pathway for androgen hormones in humans. Whether Ugt2b enzymes from mice are also reactive with these hormones have never been investigated. The present study aimed at evaluating the capability of murine tissues and Ugt2b enzymes to glucuronidated androgens. The 7 murine Ugt2b (Ugt2b1, 2b5, 2b34, 2b35, 2b36, 2b37 and 2b38) enzymes were cloned and stably expressed into HEK293 cells. In vitro glucuronidation assays were performed with microsomal proteins or homogenates from mice tissues (liver, kidney, intestine, adipose, testis, prostate, epididymis, bulbo, seminal vesicle, mammary glands, uterus, and ovary) and from Ugt2b-HEK293 cells. Male and female livers, as well as male kidneys, are the major sites for androgen glucuronidation in mice. The male liver is highly efficient at glucuronidation of dihydrotestosterone (DHT) and testosterone and is enriched in Ugt2b1 and 2b5 enzymes. Androsterone and 3α-Diol are conjugated in the male kidney through an Ugt2b37-dependent process. Interestingly, castration partially abolished hepatic Ugt2b1 expression and activity, while Ugt2b37 was totally repressed. DHT injection partially corrected these changes. In conclusion, these observations revealed the substrate- and tissue-specific manner in which murine Ugt2b enzymes conjugate androgens. They also evidence how androgens modulate their own glucuronide conjugation in mice.
- Published
- 2022
- Full Text
- View/download PDF
28. Intestinal UDP-Glucuronosyltransferase 1A1 and Protection against Irinotecan-Induced Toxicity in a Novel UDP-Glucuronosyltransferase 1A1 Tissue-Specific Humanized Mouse Model.
- Author
-
Mennillo E, Yang X, Weber AA, Maruo Y, Verreault M, Barbier O, Chen S, and Tukey RH
- Subjects
- Animals, Apoptosis drug effects, Endoplasmic Reticulum Stress drug effects, Enteritis chemically induced, Enteritis pathology, Glucuronosyltransferase genetics, Humans, Intestines enzymology, Intestines pathology, Liver enzymology, Male, Mice, Mice, Transgenic, Microsomes, Liver, Stem Cells, Glucuronosyltransferase metabolism, Intestines metabolism, Irinotecan toxicity
- Abstract
The human UDP-glucuronosyltransferases (UGTs) represent an important family of drug-metabolizing enzymes, with UGT1A1 targeting the conjugation and detoxification of many exogenous substances, including pharmaceutical drugs. In this study we generated humanized UGT1A1 mice expressing the human UGT1A1 gene in either liver ( hUGT1A1
HEP ) or intestine ( hUGT1A1GI ), enabling experiments to examine tissue-specific properties of UGT1A1-specific glucuronidation. Hepatic and intestinal tissue-specific expression and function of UGT1A1 were demonstrated. Although the liver is considered a major organ for detoxification, intestinal UGT1A1 is an important contributor for drug clearance. Mice were challenged with irinotecan (CPT-11), a prodrug hydrolyzed by carboxylesterases to form the active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) and detoxified by UGT1A1. Humanized UGT1A1HEP mice that have no intestinal UGT1A1 displayed a greater lethality rate when exposed to CPT-11 than hUGT1A1GI mice. When exposed to a low dose of CPT-11 (10 mg/kg), hUGT1A1HEP mice displayed greater intestinal inflammatory (IL-1 β and IL-6) insult in addition to p53-triggered apoptotic responses. In vitro studies with intestinal crypt organoids exposed to CPT-11 confirmed the results observed in vivo and indicated that CPT-11 impacts stemness, apoptosis, and endoplasmic reticulum (ER) stress in organoids deficient in UGT1A1. When we examined the induction of ER stress in organoids with thapsigargin, an inhibitor of sarco/endoplasmic reticulum Ca2+ ATPase, apoptosis and the caspase surge that occurred in hUGT1A1HEP mice were blocked in hUGT1A1GI organoids. This study reveals the importance of intestinal UGT1A1 in preventing inflammation, apoptosis, and loss of stemness capacity upon systemic challenge with an important chemotherapeutic agent. SIGNIFICANCE STATEMENT: Hepatic and intestinal UGT1A1 play a key role in the metabolism and detoxification of endogenous and exogenous compounds. The use of tissue-specific humanized models expressing UGT1A1 in liver or intestine has confirmed the relevance of the intestinal tract in the detoxification of irinotecan. Mechanistic studies using intestinal organoids highlighted the importance of UGT1A1 in reducing inflammation, apoptosis, and loss of stemness. These new models provide valuable tools for studying tissue-specific glucuronidation of substances that are metabolized by human UGT1A1., (Copyright © 2021 by The American Society for Pharmacology and Experimental Therapeutics.)- Published
- 2022
- Full Text
- View/download PDF
29. Heterogeneity of Response to Iron-Based Metallodrugs in Glioblastoma Is Associated with Differences in Chemical Structures and Driven by FAS Expression Dynamics and Transcriptomic Subtypes.
- Author
-
Vessières A, Quissac E, Lemaire N, Alentorn A, Domeracka P, Pigeon P, Sanson M, Idbaih A, and Verreault M
- Subjects
- Cell Line, Tumor, Humans, Structure-Activity Relationship, Biomarkers, Tumor biosynthesis, Ferrous Compounds pharmacology, Gene Expression Regulation, Neoplastic drug effects, Glioblastoma drug therapy, Glioblastoma metabolism, Glioblastoma pathology, Tamoxifen pharmacology, Transcriptome drug effects
- Abstract
Glioblastoma (GBM) is the most frequent and deadliest primary brain cancer in adults, justifying the search for new treatments. Some members of the iron-based ferrocifen family have demonstrated a high cytotoxic effect on various cancer cell lines via innovative mechanisms of action. Here, we evaluated the antiproliferative activity by wst-1 assay of six ferrocifens in 15 molecularly diverse GBM patient-derived cell lines (PDCLs). In five out of six compounds, the half maximal inhibitory concentration (IC
50 ) values varied significantly (10 nM < IC50 < 29.8 µM) while the remaining one (the tamoxifen-like complex) was highly cytotoxic against all PDCLs (mean IC50 = 1.28 µM). The pattern of response was comparable for the four ferrocifens bearing at least one phenol group and differed widely from those of the tamoxifen-like complex and the complex with no phenol group. An RNA sequencing differential analysis showed that response to the diphenol ferrocifen relied on the activation of the Death Receptor signaling pathway and the modulation of FAS expression. Response to this complex was greater in PDCLs from the Mesenchymal or Proneural transcriptomic subtypes compared to the ones from the Classical subtype. These results provide new information on the mechanisms of action of ferrocifens and highlight a broader diversity of behavior than previously suspected among members of this family. They also support the case for a molecular-based personalized approach to future use of ferrocifens in the treatment of GBM.- Published
- 2021
- Full Text
- View/download PDF
30. SLIT2/ROBO signaling in tumor-associated microglia and macrophages drives glioblastoma immunosuppression and vascular dysmorphia.
- Author
-
Geraldo LH, Xu Y, Jacob L, Pibouin-Fragner L, Rao R, Maissa N, Verreault M, Lemaire N, Knosp C, Lesaffre C, Daubon T, Dejaegher J, Solie L, Rudewicz J, Viel T, Tavitian B, De Vleeschouwer S, Sanson M, Bikfalvi A, Idbaih A, Lu QR, Lima FR, Thomas JL, Eichmann A, and Mathivet T
- Subjects
- Animals, Brain Neoplasms blood supply, Brain Neoplasms pathology, Disease Progression, Gene Expression Regulation, Neoplastic, Gene Knockdown Techniques, Glioblastoma blood supply, Glioblastoma pathology, Heterografts, Humans, Immune Tolerance, Intercellular Signaling Peptides and Proteins deficiency, Intercellular Signaling Peptides and Proteins genetics, Macrophages immunology, Mice, Mice, Inbred C57BL, Microglia immunology, Nerve Tissue Proteins deficiency, Nerve Tissue Proteins genetics, Prognosis, Signal Transduction immunology, Tumor Microenvironment immunology, Roundabout Proteins, Brain Neoplasms immunology, Glioblastoma immunology, Intercellular Signaling Peptides and Proteins immunology, Nerve Tissue Proteins immunology, Receptors, Immunologic immunology
- Abstract
SLIT2 is a secreted polypeptide that guides migration of cells expressing Roundabout 1 and 2 (ROBO1 and ROBO2) receptors. Herein, we investigated SLIT2/ROBO signaling effects in gliomas. In patients with glioblastoma (GBM), SLIT2 expression increased with malignant progression and correlated with poor survival and immunosuppression. Knockdown of SLIT2 in mouse glioma cells and patient-derived GBM xenografts reduced tumor growth and rendered tumors sensitive to immunotherapy. Tumor cell SLIT2 knockdown inhibited macrophage invasion and promoted a cytotoxic gene expression profile, which improved tumor vessel function and enhanced efficacy of chemotherapy and immunotherapy. Mechanistically, SLIT2 promoted microglia/macrophage chemotaxis and tumor-supportive polarization via ROBO1- and ROBO2-mediated PI3K-γ activation. Macrophage Robo1 and Robo2 deletion and systemic SLIT2 trap delivery mimicked SLIT2 knockdown effects on tumor growth and the tumor microenvironment (TME), revealing SLIT2 signaling through macrophage ROBOs as a potentially novel regulator of the GBM microenvironment and immunotherapeutic target for brain tumors.
- Published
- 2021
- Full Text
- View/download PDF
31. Transcriptional CDK inhibitors, CYC065 and THZ1 promote Bim-dependent apoptosis in primary and recurrent GBM through cell cycle arrest and Mcl-1 downregulation.
- Author
-
Juric V, Hudson L, Fay J, Richards CE, Jahns H, Verreault M, Bielle F, Idbaih A, Lamfers MLM, Hopkins AM, Rehm M, and Murphy BM
- Subjects
- Adenosine pharmacology, Animals, Cell Line, Tumor, Cell Proliferation drug effects, Cell Survival drug effects, Chick Embryo, Cyclin-Dependent Kinases antagonists & inhibitors, Cyclin-Dependent Kinases metabolism, Down-Regulation drug effects, Gene Expression Regulation, Neoplastic drug effects, Glioblastoma genetics, Humans, Myeloid Cell Leukemia Sequence 1 Protein metabolism, Neurons drug effects, Neurons metabolism, Neurons pathology, RNA, Messenger genetics, RNA, Messenger metabolism, Spheroids, Cellular drug effects, Spheroids, Cellular metabolism, Spheroids, Cellular pathology, Transcription, Genetic drug effects, Xenograft Model Antitumor Assays, Adenosine analogs & derivatives, Apoptosis drug effects, Apoptosis genetics, Bcl-2-Like Protein 11 metabolism, Cell Cycle Checkpoints drug effects, Cell Cycle Checkpoints genetics, Glioblastoma pathology, Myeloid Cell Leukemia Sequence 1 Protein genetics, Neoplasm Recurrence, Local pathology, Phenylenediamines pharmacology, Protein Kinase Inhibitors pharmacology, Pyrimidines pharmacology
- Abstract
Activation of cyclin-dependent kinases (CDKs) contributes to the uncontrolled proliferation of tumour cells. Genomic alterations that lead to the constitutive activation or overexpression of CDKs can support tumourigenesis including glioblastoma (GBM), the most common and aggressive primary brain tumour in adults. The incurability of GBM highlights the need to discover novel and more effective treatment options. Since CDKs 2, 7 and 9 were found to be overexpressed in GBM, we tested the therapeutic efficacy of two CDK inhibitors (CKIs) (CYC065 and THZ1) in a heterogeneous panel of GBM patient-derived cell lines (PDCLs) cultured as gliomaspheres, as preclinically relevant models. CYC065 and THZ1 treatments suppressed invasion and induced viability loss in the majority of gliomaspheres, irrespective of the mutational background of the GBM cases, but spared primary cortical neurons. Viability loss arose from G2/M cell cycle arrest following treatment and subsequent induction of apoptotic cell death. Treatment efficacies and treatment durations required to induce cell death were associated with proliferation velocities, and apoptosis induction correlated with complete abolishment of Mcl-1 expression, a cell cycle-regulated antiapoptotic Bcl-2 family member. GBM models generally appeared highly dependent on Mcl-1 expression for cell survival, as demonstrated by pharmacological Mcl-1 inhibition or depletion of Mcl-1 expression. Further analyses identified CKI-induced Mcl-1 loss as a prerequisite to establish conditions at which the BH3-only protein Bim can efficiently induce apoptosis, with cellular Bim amounts strongly correlating with treatment efficacy. CKIs reduced proliferation and promoted apoptosis also in chick embryo xenograft models of primary and recurrent GBM. Collectively, these studies highlight the potential of these novel CKIs to suppress growth and induce cell death of patient-derived GBM cultures in vitro and in vivo, warranting further clinical investigation., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
32. Omega-3 Polyunsaturated Fatty Acid: A Pharmaco-Nutraceutical Approach to Improve the Responsiveness to Ursodeoxycholic Acid.
- Author
-
Thérien A, Cieślak A, Verreault M, Perreault M, Trottier J, Gobeil S, Vohl MC, and Barbier O
- Subjects
- Apoptosis drug effects, Autoimmune Diseases, Bile Acids and Salts metabolism, Bile Acids and Salts toxicity, Carcinoma, Hepatocellular, Caspase 3, Cholangitis, Sclerosing, Cholestanetriol 26-Monooxygenase genetics, Cholestasis, Cholesterol 7-alpha-Hydroxylase genetics, Down-Regulation drug effects, Drug Therapy, Combination, Endoplasmic Reticulum Stress drug effects, Gene Expression drug effects, Hep G2 Cells, Humans, Inflammation, Liver metabolism, Liver Cirrhosis, Biliary, Liver Diseases, THP-1 Cells, Dietary Supplements, Fatty Acids, Omega-3 metabolism, Fatty Acids, Omega-3 pharmacology, Ursodeoxycholic Acid pharmacology
- Abstract
Ursodeoxycholic acid (UDCA) is the first line therapy for the treatment of cholestatic and autoimmune liver diseases. Its clinical use is currently limited by a significant proportion of non-responder patients. Polyunsaturated fatty acids (n-3 PUFAs) possess important anti-inflammatory properties and protect liver cells against bile acid (BA)-induced toxicity. The present study was designed to rapidly evaluate whether combining n-3 PUFAs (i.e., eicosapentaenoic [EPA] and docosahexaenoic [DHA] acids) to UDCA would provide additional benefits when compared to the drug alone. The parameters evaluated were (i) the expression of genes governing BA synthesis, transport, and metabolism; (ii) the prevention of BA-induced apoptosis and endoplasmic reticulum (ER)-stress; and (iii) the control of BA- and LPS-dependent inflammation. In the absence of n-3 PUFAs, most of the parameters investigated were unaffected by UDCA or were only altered by the higher dose (500 µM) of the drug. By contrast, in the presence of EPA/DHA (50/50 µM), all parameters showed a strongly improved response and the lowest UDCA dosage (50 µM) provided equal or better benefits than the highest dose used alone. For example, the combination EPA/DHA + UDCA 50 µM caused comparable down-regulation of the CYP7A1 gene expression and of the BA-induced caspase 3 activity as observed with UDCA 500 µM. In conclusion, these results suggest that the addition of n-3 PUFAs to UDCA may improve the response to the drug, and that such a pharmaco-nutraceutical approach could be used in clinic to open the narrow therapeutic dose of UDCA in cholestatic liver diseases.
- Published
- 2021
- Full Text
- View/download PDF
33. Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist.
- Author
-
Boccellato C, Kolbe E, Peters N, Juric V, Fullstone G, Verreault M, Idbaih A, Lamfers MLM, Murphy BM, and Rehm M
- Subjects
- Brain Neoplasms metabolism, Brain Neoplasms pathology, CASP8 and FADD-Like Apoptosis Regulating Protein metabolism, Caspase 8 metabolism, Cell Line, Tumor, Drug Resistance, Neoplasm, Glioma metabolism, Glioma pathology, Humans, Myeloid Cell Leukemia Sequence 1 Protein antagonists & inhibitors, Myeloid Cell Leukemia Sequence 1 Protein metabolism, Pyrimidines pharmacology, Receptors, TNF-Related Apoptosis-Inducing Ligand metabolism, Signal Transduction, Spheroids, Cellular, Thiophenes pharmacology, Time Factors, Antineoplastic Combined Chemotherapy Protocols pharmacology, Apoptosis drug effects, Brain Neoplasms drug therapy, Glioma drug therapy, Lactones pharmacology, Proteasome Inhibitors pharmacology, Pyrroles pharmacology, Receptors, TNF-Related Apoptosis-Inducing Ligand agonists
- Abstract
Due to the absence of curative treatments for glioblastoma (GBM), we assessed the efficacy of single and combination treatments with a translationally relevant 2nd generation TRAIL-receptor agonist (IZI1551) and the blood-brain barrier (BBB) permeant proteasome inhibitor marizomib in a panel of patient-derived glioblastoma cell lines. These cells were cultured using protocols that maintain the characteristics of primary tumor cells. IZI1551+marizomib combination treatments synergistically induced apoptotic cell death in the majority of cases, both in 2D, as well as in 3D spheroid cultures. In contrast, single-drug treatments largely failed to induce noticeable amounts of cell death. Kinetic analyses suggested that time-shifted drug exposure might further increase responsiveness, with marizomib pre-treatments indeed strongly enhancing cell death. Cell death responses upon the addition of IZI1551 could also be observed in GBM cells that were kept in a medium collected from the basolateral side of a human hCMEC/D3 BBB model that had been exposed to marizomib. Interestingly, the subset of GBM cell lines resistant to IZI1551+marizomib treatments expressed lower surface amounts of TRAIL death receptors, substantially lower amounts of procaspase-8, and increased amounts of cFLIP, suggesting that apoptosis initiation was likely too weak to initiate downstream apoptosis execution. Indeed, experiments in which the mitochondrial apoptosis threshold was lowered by antagonizing Mcl-1 re-established sensitivity to IZI1551+marizomib in otherwise resistant cells. Overall, our study demonstrates a high efficacy of combination treatments with a latest-generation TRAIL receptor agonist and the BBB permeant proteasome inhibitor marizomib in relevant GBM cell models, as well as strategies to further enhance responsiveness and to sensitize subgroups of otherwise resistant GBM cases.
- Published
- 2021
- Full Text
- View/download PDF
34. High-Fat Diet Modulates Hepatic Amyloid β and Cerebrosterol Metabolism in the Triple Transgenic Mouse Model of Alzheimer's Disease.
- Author
-
Bosoi CR, Vandal M, Tournissac M, Leclerc M, Fanet H, Mitchell PL, Verreault M, Trottier J, Virgili J, Tremblay C, Lippman HR, Bajaj JS, Barbier O, Marette A, and Calon F
- Subjects
- Alzheimer Disease etiology, Animals, Brain metabolism, Brain-Gut Axis physiology, Disease Models, Animal, Lipogenesis physiology, Mice, Mice, Obese, Mice, Transgenic, Alzheimer Disease metabolism, Amyloid beta-Peptides metabolism, Diet, High-Fat adverse effects, Hydroxycholesterols metabolism, Liver metabolism
- Abstract
Obesity and diabetes are strongly associated not only with fatty liver but also cognitive dysfunction. Moreover, their presence, particularly in midlife, is recognized as a risk factor for Alzheimer's disease (AD). AD, the most common cause of dementia, is increasingly considered as a metabolic disease, although underlying pathogenic mechanisms remain unclear. The liver plays a major role in maintaining glucose and lipid homeostasis, as well as in clearing the AD neuropathogenic factor amyloid-β (Aβ) and in metabolizing cerebrosterol, a cerebral-derived oxysterol proposed as an AD biomarker. We hypothesized that liver impairment induced by obesity contributes to AD pathogenesis. We show that the AD triple transgenic mouse model (3xTg-AD) fed a chow diet presents a hepatic phenotype similar to nontransgenic controls (NTg) at 15 months of age. A high-fat diet (HFD), started at the age of 6 months and continued for 9 months, until sacrifice, induced hepatic steatosis in NTg, but not in 3xTg-AD mice, whereas HFD did not induce changes in hepatic fatty acid oxidation, de novo lipogenesis, and gluconeogenesis. HFD-induced obesity was associated with a reduction of insulin-degrading enzyme, one of the main hepatic enzymes responsible for Aβ clearance. The hepatic rate of cerebrosterol glucuronidation was lower in obese 3xTg-AD than in nonobese controls ( P < 0.05) and higher compared with obese NTg ( P < 0.05), although circulating levels remained unchanged. Conclusion: Modulation of hepatic lipids, Aβ, and cerebrosterol metabolism in obese 3xTg-AD mice differs from control mice. This study sheds light on the liver-brain axis, showing that the chronic presence of NAFLD and changes in liver function affect peripheral AD features and should be considered during development of biomarkers or AD therapeutic targets., (© 2020 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.)
- Published
- 2020
- Full Text
- View/download PDF
35. Phenotypic selection through cell death: stochastic modelling of O-6-methylguanine-DNA methyltransferase dynamics.
- Author
-
Lasri A, Juric V, Verreault M, Bielle F, Idbaih A, Kel A, Murphy B, and Sturrock M
- Abstract
Glioblastoma (GBM) is the most aggressive malignant primary brain tumour with a median overall survival of 15 months. To treat GBM, patients currently undergo a surgical resection followed by exposure to radiotherapy and concurrent and adjuvant temozolomide (TMZ) chemotherapy. However, this protocol often leads to treatment failure, with drug resistance being the main reason behind this. To date, many studies highlight the role of O-6-methylguanine-DNA methyltransferase (MGMT) in conferring drug resistance. The mechanism through which MGMT confers resistance is not well studied-particularly in terms of computational models. With only a few reasonable biological assumptions, we were able to show that even a minimal model of MGMT expression could robustly explain TMZ-mediated drug resistance. In particular, we showed that for a wide range of parameter values constrained by novel cell growth and viability assays, a model accounting for only stochastic gene expression of MGMT coupled with cell growth, division, partitioning and death was able to exhibit phenotypic selection of GBM cells expressing MGMT in response to TMZ. Furthermore, we found this selection allowed the cells to pass their acquired phenotypic resistance onto daughter cells in a stable manner (as long as TMZ is provided). This suggests that stochastic gene expression alone is enough to explain the development of chemotherapeutic resistance., Competing Interests: The authors declare that they have no competing interests., (© 2020 The Authors.)
- Published
- 2020
- Full Text
- View/download PDF
36. Mechanisms and therapeutic implications of hypermutation in gliomas.
- Author
-
Touat M, Li YY, Boynton AN, Spurr LF, Iorgulescu JB, Bohrson CL, Cortes-Ciriano I, Birzu C, Geduldig JE, Pelton K, Lim-Fat MJ, Pal S, Ferrer-Luna R, Ramkissoon SH, Dubois F, Bellamy C, Currimjee N, Bonardi J, Qian K, Ho P, Malinowski S, Taquet L, Jones RE, Shetty A, Chow KH, Sharaf R, Pavlick D, Albacker LA, Younan N, Baldini C, Verreault M, Giry M, Guillerm E, Ammari S, Beuvon F, Mokhtari K, Alentorn A, Dehais C, Houillier C, Laigle-Donadey F, Psimaras D, Lee EQ, Nayak L, McFaline-Figueroa JR, Carpentier A, Cornu P, Capelle L, Mathon B, Barnholtz-Sloan JS, Chakravarti A, Bi WL, Chiocca EA, Fehnel KP, Alexandrescu S, Chi SN, Haas-Kogan D, Batchelor TT, Frampton GM, Alexander BM, Huang RY, Ligon AH, Coulet F, Delattre JY, Hoang-Xuan K, Meredith DM, Santagata S, Duval A, Sanson M, Cherniack AD, Wen PY, Reardon DA, Marabelle A, Park PJ, Idbaih A, Beroukhim R, Bandopadhayay P, Bielle F, and Ligon KL
- Subjects
- Animals, Antineoplastic Agents, Alkylating pharmacology, Antineoplastic Agents, Alkylating therapeutic use, Brain Neoplasms immunology, DNA Mismatch Repair genetics, Gene Frequency, Genome, Human drug effects, Genome, Human genetics, Glioma immunology, Humans, Male, Mice, Microsatellite Repeats drug effects, Microsatellite Repeats genetics, Mutagenesis drug effects, Phenotype, Prognosis, Programmed Cell Death 1 Receptor antagonists & inhibitors, Sequence Analysis, DNA, Temozolomide pharmacology, Temozolomide therapeutic use, Xenograft Model Antitumor Assays, Brain Neoplasms genetics, Brain Neoplasms therapy, Glioma genetics, Glioma therapy, Mutation drug effects
- Abstract
A high tumour mutational burden (hypermutation) is observed in some gliomas
1-5 ; however, the mechanisms by which hypermutation develops and whether it predicts the response to immunotherapy are poorly understood. Here we comprehensively analyse the molecular determinants of mutational burden and signatures in 10,294 gliomas. We delineate two main pathways to hypermutation: a de novo pathway associated with constitutional defects in DNA polymerase and mismatch repair (MMR) genes, and a more common post-treatment pathway, associated with acquired resistance driven by MMR defects in chemotherapy-sensitive gliomas that recur after treatment with the chemotherapy drug temozolomide. Experimentally, the mutational signature of post-treatment hypermutated gliomas was recapitulated by temozolomide-induced damage in cells with MMR deficiency. MMR-deficient gliomas were characterized by a lack of prominent T cell infiltrates, extensive intratumoral heterogeneity, poor patient survival and a low rate of response to PD-1 blockade. Moreover, although bulk analyses did not detect microsatellite instability in MMR-deficient gliomas, single-cell whole-genome sequencing analysis of post-treatment hypermutated glioma cells identified microsatellite mutations. These results show that chemotherapy can drive the acquisition of hypermutated populations without promoting a response to PD-1 blockade and supports the diagnostic use of mutational burden and signatures in cancer.- Published
- 2020
- Full Text
- View/download PDF
37. Differential Role of Liver X Receptor (LXR) α and LXR β in the Regulation of UDP-Glucuronosyltransferase 1A1 in Humanized UGT1 Mice.
- Author
-
Hansmann E, Mennillo E, Yoda E, Verreault M, Barbier O, Chen S, and Tukey RH
- Subjects
- Animals, Animals, Newborn, Bilirubin blood, Bilirubin metabolism, Female, Gene Expression Regulation, Developmental drug effects, Glucuronosyltransferase genetics, Hydrocarbons, Fluorinated administration & dosage, Liver X Receptors agonists, Liver X Receptors genetics, Male, Mice, Mice, Transgenic, Sulfonamides administration & dosage, Uridine Diphosphate Glucuronic Acid metabolism, Gene Expression Regulation, Developmental physiology, Glucuronosyltransferase metabolism, Liver X Receptors metabolism
- Abstract
Liver X receptors (LXRs), LXR α and LXR β , are nuclear receptors that regulate the metabolism of cholesterol and bile acids and are activated by oxysterols. Humanized UGT1 ( hUGT1 ) mice express the 9-human UGT1A genes associated with the UGT1 locus in a Ugt1 -null background. The expression of UGT1A1 is developmentally delayed in the liver and intestines, resulting in the accumulation of serum bilirubin during the neonatal period. Induction of UGT1A1 in newborn hUGT1 mice leads to rapid reduction in total serum bilirubin (TSB) levels, a phenotype measurement that allows for an accurate prediction on UGT1A1 expression. When neonatal hUGT1 mice were treated by oral gavage with the LXR agonist T0901317, TSB levels were dramatically reduced. To determine the LXR contribution to the induction of UGT1A1 and the lowering of TSB levels, experiments were conducted in neonatal hUGT1/Lxrα
-/- , hUGT1/Lxrβ-/- , and hUGT1/Lxrαβ-/- mice treated with T0901317. Induction of liver UGT1A1 was dependent upon LXR α , with the induction pattern paralleling induction of LXR α -specific stearoyl CoA desaturase 1. However, the actions of T0901317 were also shown to display a lack of specificity for LXR, with the induction of liver UGT1A1 in hUGT1/Lxrαβ-/- mice, a result associated with activation of both pregnane X receptor and constitutive androstane receptor. However, the LXR agonist GW3965 was highly selective toward LXR α , showing no impact on lowering TSB values or inducing UGT1A1 in hUGT1/Lxrα-/- mice. An LXR-specific enhancer site on the UGT1A1 gene was identified, along with convincing evidence that LXR α is crucial in maintaining constitutive expression of UGT1A1 in adult hUGT1 mice. SIGNIFICANCE STATEMENT: It has been established that activation of LXR α , and not LXR β , is responsible for the induction of liver UGT1A1 and metabolism of serum bilirubin in neonatal hUGT1 mice. Although induction of the human UGT1A1 gene is initiated at a newly characterized LXR enhancer site, allelic deletion of the Lxrα gene drastically reduces the constitutive expression of liver UGT1A1 in adult hUGT1 mice. Combined, these findings indicate that LXR α is critical for the developmental expression of UGT1A1., (Copyright © 2020 by The American Society for Pharmacology and Experimental Therapeutics.)- Published
- 2020
- Full Text
- View/download PDF
38. Dissecting the role of crosstalk between glioblastoma subpopulations in tumor cell spreading.
- Author
-
Jubran MR, Rubinstein AM, Cojocari I, Adejumobi IA, Mogilevsky M, Tibi S, Sionov RV, Verreault M, Idbaih A, Karni R, and Kravchenko-Balasha N
- Abstract
Glioblastoma (GBM) is a highly infiltrative brain cancer, which is thus difficult to operate. GBM cells frequently harbor Epidermal Growth Factor Receptor amplification (EGFRwt) and/or activating mutation (EGFRvIII), generating at least two different cellular subpopulations within the tumor. We examined the relationship between the diffusive architectures of GBM tumors and the paracrine interactions between those subpopulations. Our aim was to shed light on what drives GBM cells to reach large cell-cell distances, and whether this characteristic can be manipulated. We established a methodology that quantifies the infiltration abilities of cancer cells through computation of cell-cell separation distance distributions in 3D. We found that aggressive EGFRvIII cells modulate the migration and infiltrative properties of EGFRwt cells. EGFRvIII cells secrete HGF and IL6, leading to enhanced activity of Src protein in EGFRwt cells, and rendering EGFRwt cells higher velocity and augmented ability to spread. Src inhibitor, dasatinib, at low non-toxic concentrations, reduced the infiltrative properties of EGFRvIII/EGFRwt neurospheres. Furthermore, dasatinib treatment induced compact multicellular microstructure packing of EGFRvIII/EGFRwt cells, impairing their ability to spread. Prevention of cellular infiltration or induction of compact microstructures may assist the detection of GBM tumors and tumor remnants in the brains and improve their surgical removal.
- Published
- 2020
- Full Text
- View/download PDF
39. Temporary blood-brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma.
- Author
-
Dréan A, Lemaire N, Bouchoux G, Goldwirt L, Canney M, Goli L, Bouzidi A, Schmitt C, Guehennec J, Verreault M, Sanson M, Delattre JY, Mokhtari K, Sottilini F, Carpentier A, and Idbaih A
- Subjects
- Animals, Antineoplastic Agents pharmacokinetics, Apoptosis, Blood-Brain Barrier metabolism, Blood-Brain Barrier radiation effects, Brain Neoplasms metabolism, Brain Neoplasms pathology, Carboplatin pharmacokinetics, Cell Proliferation, Female, Glioblastoma metabolism, Glioblastoma pathology, Humans, Mice, Mice, Nude, Tissue Distribution, Tumor Cells, Cultured, Xenograft Model Antitumor Assays, Antineoplastic Agents pharmacology, Blood-Brain Barrier drug effects, Brain Neoplasms drug therapy, Carboplatin pharmacology, Disease Models, Animal, Glioblastoma drug therapy, Ultrasonic Waves
- Abstract
Introduction: Glioblastoma (GBM) is the most common and aggressive primary brain cancer in adults. Few cytotoxic chemotherapies have been shown to be effective against GBM, due in part to the presence of the blood-brain barrier (BBB), which reduces the penetration of chemotherapies from the blood to the brain. Ultrasound-induced BBB opening (US-BBB) has been shown to increase the penetration of multiple chemotherapeutic agents in the brain in animal models. In the current study, the anti-tumor activity of carboplatin chemotherapy with and without US-BBB was investigated in several GBM mouse models., Methods: First, the IC50 of two commercial (U87 and U251) and six patient-derived GBM cell lines (PDCL) to carboplatin was measured. Next, U87 was subcutaneously grafted to a nude mouse model to test the in vivo response of the tumor to carboplatin in the absence of the BBB. Lastly, nude mice bearing orthotopically xenografted GBM cell lines (U87 or a PDCL) were randomized to four experimental groups: (i) untreated, (ii) US-BBB alone, (iii) carboplatin alone and, (iv) carboplatin + US-BBB. Mice were treated once weekly for 4 weeks and monitored for toxicity, tumor growth, and survival., Results: Carboplatin plus US-BBB enhanced survival (p = 0.03) and delayed tumor growth (p < 0.05) of GBM-bearing mice compared to carboplatin alone, with a 4.2-fold increase of carboplatin penetration in the brain, without evidence of significant neurological or systemic toxicity., Conclusions: Carboplatin efficacy was enhanced in GBM mouse models with US-BBB and appears to be a promising chemotherapy for this approach.
- Published
- 2019
- Full Text
- View/download PDF
40. Correction to: ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma.
- Author
-
Dréan A, Rosenberg S, Lejeune FX, Goli L, Nadaradjane AA, Guehennec J, Schmitt C, Verreault M, Bielle F, Mokhtari K, Sanson M, Carpentier A, Delattre JY, and Idbaih A
- Abstract
The names of authors Marc Sanson and Jean-Yves Delattre were incorrectly presented in the initial online publication. The original article has been corrected.
- Published
- 2018
- Full Text
- View/download PDF
41. ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma.
- Author
-
Dréan A, Rosenberg S, Lejeune FX, Goli L, Nadaradjane AA, Guehennec J, Schmitt C, Verreault M, Bielle F, Mokhtari K, Sanson M, Carpentier A, Delattre JY, and Idbaih A
- Subjects
- Antineoplastic Agents, Alkylating pharmacology, Biomarkers, Tumor genetics, Biomarkers, Tumor metabolism, Brain Neoplasms genetics, Brain Neoplasms mortality, Brain Neoplasms therapy, Cell Line, Tumor, Chemoradiotherapy, Cohort Studies, DNA Methylation, DNA Modification Methylases genetics, DNA Modification Methylases metabolism, DNA Repair Enzymes genetics, DNA Repair Enzymes metabolism, Drug Resistance, Neoplasm physiology, Gene Expression Regulation, Neoplastic, Glioblastoma genetics, Glioblastoma mortality, Glioblastoma therapy, Humans, Prognosis, Promoter Regions, Genetic, RNA, Messenger metabolism, Survival Analysis, Temozolomide pharmacology, Tumor Microenvironment, Tumor Suppressor Proteins genetics, Tumor Suppressor Proteins metabolism, ATP-Binding Cassette Transporters metabolism, Brain Neoplasms metabolism, Glioblastoma metabolism
- Abstract
ATP-binding cassette transporters (ABC transporters) regulate traffic of multiple compounds, including chemotherapeutic agents, through biological membranes. They are expressed by multiple cell types and have been implicated in the drug resistance of some cancer cells. Despite significant research in ABC transporters in the context of many diseases, little is known about their expression and clinical value in glioblastoma (GBM). We analyzed expression of 49 ABC transporters in both commercial and patient-derived GBM cell lines as well as from 51 human GBM tumor biopsies. Using The Cancer Genome Atlas (TCGA) cohort as a training dataset and our cohort as a validation dataset, we also investigated the prognostic value of these ABC transporters in newly diagnosed GBM patients, treated with the standard of care. In contrast to commercial GBM cell lines, GBM-patient derived cell lines (PDCL), grown as neurospheres in a serum-free medium, express ABC transporters similarly to parental tumors. Serum appeared to slightly increase resistance to temozolomide correlating with a tendency for an increased expression of ABCB1. Some differences were observed mainly due to expression of ABC transporters by microenvironmental cells. Together, our data suggest that the efficacy of chemotherapeutic agents may be misestimated in vitro if they are the targets of efflux pumps whose expression can be modulated by serum. Interestingly, several ABC transporters have prognostic value in the TCGA dataset. In our cohort of 51 GBM patients treated with radiation therapy with concurrent and adjuvant temozolomide, ABCA13 overexpression is associated with a decreased progression free survival in univariate (p < 0.01) and multivariate analyses including MGMT promoter methylation (p = 0.05) suggesting reduced sensitivity to temozolomide in ABCA13 overexpressing GBM. Expression of ABC transporters is: (i) detected in GBM and microenvironmental cells and (ii) better reproduced in GBM-PDCL. ABCA13 expression is an independent prognostic factor in newly diagnosed GBM patients. Further prospective studies are warranted to investigate whether ABCA13 expression can be used to further personalize treatments for GBM.
- Published
- 2018
- Full Text
- View/download PDF
42. A recurrent point mutation in PRKCA is a hallmark of chordoid gliomas.
- Author
-
Rosenberg S, Simeonova I, Bielle F, Verreault M, Bance B, Le Roux I, Daniau M, Nadaradjane A, Gleize V, Paris S, Marie Y, Giry M, Polivka M, Figarella-Branger D, Aubriot-Lorton MH, Villa C, Vasiljevic A, Lechapt-Zalcman E, Kalamarides M, Sharif A, Mokhtari K, Pagnotta SM, Iavarone A, Lasorella A, Huillard E, and Sanson M
- Subjects
- Adult, Aged, Cell Proliferation, Cells, Cultured, Cerebral Ventricle Neoplasms metabolism, Female, Glioma metabolism, Humans, Male, Middle Aged, Point Mutation, Protein Kinase C-alpha metabolism, Cerebral Ventricle Neoplasms genetics, Glioma genetics, Protein Kinase C-alpha genetics
- Abstract
Chordoid glioma (ChG) is a characteristic, slow growing, and well-circumscribed diencephalic tumor, whose mutational landscape is unknown. Here we report the analysis of 16 ChG by whole-exome and RNA-sequencing. We found that 15 ChG harbor the same PRKCA
D463H mutation. PRKCA encodes the Protein kinase C (PKC) isozyme alpha (PKCα) and is mutated in a wide range of human cancers. However the hot spot PRKCAD463H mutation was not described in other tumors. PRKCAD463H is strongly associated with the activation of protein translation initiation (EIF2) pathway. PKCαD463H mRNA levels are more abundant than wild-type PKCα transcripts, while PKCαD463H is less stable than the PCKαWT protein. Compared to PCKαWT , the PKCαD463H protein is depleted from the cell membrane. The PKCαD463H mutant enhances proliferation of astrocytes and tanycytes, the cells of origin of ChG. In conclusion, our study identifies the hallmark mutation for chordoid gliomas and provides mechanistic insights on ChG oncogenesis.- Published
- 2018
- Full Text
- View/download PDF
43. Urinary Elimination of Bile Acid Glucuronides under Severe Cholestatic Situations: Contribution of Hepatic and Renal Glucuronidation Reactions.
- Author
-
Perreault M, Wunsch E, Białek A, Trottier J, Verreault M, Caron P, Poirier GG, Milkiewicz P, and Barbier O
- Subjects
- Aged, Cholestasis blood, Cholestasis therapy, Female, Glucuronides blood, Glucuronosyltransferase genetics, Humans, Kidney enzymology, Male, Microsomes, Liver enzymology, Middle Aged, Stents, Bile Acids and Salts metabolism, Cholestasis urine, Glucuronides urine, Glucuronosyltransferase metabolism, RNA, Messenger metabolism
- Abstract
Biliary obstruction, a severe cholestatic complication, causes accumulation of toxic bile acids (BAs) in liver cells. Glucuronidation, catalyzed by UDP-glucuronosyltransferase (UGT) enzymes, detoxifies cholestatic BAs. Using liquid chromatography coupled to tandem mass spectrometry, 11 BA glucuronide (-G) species were quantified in prebiliary and postbiliary stenting serum and urine samples from 17 patients with biliary obstruction. Stenting caused glucuronide- and fluid-specific changes in BA-G levels and BA-G/BA metabolic ratios. In vitro glucuronidation assays with human liver and kidney microsomes revealed that even if renal enzymes generally displayed lower K
M values, the two tissues shared similar glucuronidation capacities for BAs. By contrast, major differences between the two tissues were observed when four human BA-conjugating UGTs 1A3, 1A4, 2B4, and 2B7 were analyzed for mRNA and protein levels. Notably, the BA-24G producing UGT1A3 enzyme, abundant in the liver, was not detected in kidney microsomes. In conclusion, the circulating and urinary BA-G profiles are hugely impacted under severe cholestasis. The similar BA-glucuronidating abilities of hepatic and renal extracts suggest that both the liver and kidney may contribute to the urine BA-G pool.- Published
- 2018
- Full Text
- View/download PDF
44. N-3 Polyunsaturated Fatty Acids Stimulate Bile Acid Detoxification in Human Cell Models.
- Author
-
Cieślak A, Trottier J, Verreault M, Milkiewicz P, Vohl MC, and Barbier O
- Subjects
- Apoptosis drug effects, Biological Transport drug effects, Caco-2 Cells, Down-Regulation drug effects, Epithelial Cells, Hep G2 Cells, Homeostasis genetics, Humans, Intestinal Mucosa cytology, Kidney Tubules, Proximal cytology, Necrosis, Primary Cell Culture, Up-Regulation drug effects, Bile Acids and Salts metabolism, Docosahexaenoic Acids pharmacology, Eicosapentaenoic Acid pharmacology, Gene Expression drug effects
- Abstract
Cholestasis is characterized by the accumulation of toxic bile acids (BAs) in liver cells. The present study aimed to evaluate the effects of n-3 polyunsaturated fatty acids (n-3 PUFAs), such as docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids, on BA homeostasis and toxicity in human cell models. The effects of EPA and/or DHA on the expression of genes involved in the maintenance of BA homeostasis were analyzed in human hepatoma (HepG2) and colon carcinoma (Caco-2) cells, as well as in primary culture of human intestinal (InEpC) and renal (RPTEC) cells. Extracellular BA species were quantified in culture media using LC-MS/MS. BA-induced toxicity was evaluated using caspase-3 and flow cytometry assays. Gene expression analyses of HepG2 cells reveal that n-3 PUFAs reduce the expression of genes involved in BA synthesis (CYP7A1, CYP27A1) and uptake (NTCP) , while activating genes encoding metabolic enzymes (SULT2A1) and excretion transporters (MRP2, MRP3) . N-3 PUFAs also generate a less toxic BA pool and prevent the BA-dependent activation of apoptosis in HepG2 cells. Conclusion . The present study reveals that n-3 PUFAs stimulate BA detoxification.
- Published
- 2018
- Full Text
- View/download PDF
45. Comorbidity of ADHD and Anxiety Disorders in School-Age Children: Impact on Sleep and Response to a Cognitive-Behavioral Treatment.
- Author
-
Bériault M, Turgeon L, Labrosse M, Berthiaume C, Verreault M, Berthiaume C, and Godbout R
- Subjects
- Adolescent, Anxiety Disorders complications, Attention Deficit Disorder with Hyperactivity complications, Child, Cognition physiology, Female, Humans, Male, Schools, Sleep physiology, Surveys and Questionnaires, Treatment Outcome, Anxiety Disorders therapy, Attention Deficit Disorder with Hyperactivity therapy, Cognitive Behavioral Therapy methods, Sleep Wake Disorders complications
- Abstract
Objective: This exploratory study measured the impact of comorbid anxiety disorders on sleep in children with ADHD and tested the effect of cognitive-behavioral therapy (CBT) on these measures., Method: Fifty-seven children (8-12 years old) were assessed with the Child Sleep Habits Questionnaire. Four groups were formed: ADHD ( n = 20), ADHD + Anxiety ( n = 20), Anxiety ( n = 8), and Healthy Controls ( n = 9). A subgroup of 10 children with ADHD + Anxiety underwent CBT for anxiety., Results: The results showed that sleep difficulties were better associated with anxiety than with ADHD. CBT reduced sleep onset latency and marginally decreased the total amount of sleep problems., Conclusion: The present study demonstrates that comorbid anxiety in ADHD children is linked with specific sleep disturbances and is sensitive to CBT aimed at reducing anxiety.
- Published
- 2018
- Full Text
- View/download PDF
46. A driver role for GABA metabolism in controlling stem and proliferative cell state through GHB production in glioma.
- Author
-
El-Habr EA, Dubois LG, Burel-Vandenbos F, Bogeas A, Lipecka J, Turchi L, Lejeune FX, Coehlo PL, Yamaki T, Wittmann BM, Fareh M, Mahfoudhi E, Janin M, Narayanan A, Morvan-Dubois G, Schmitt C, Verreault M, Oliver L, Sharif A, Pallud J, Devaux B, Puget S, Korkolopoulou P, Varlet P, Ottolenghi C, Plo I, Moura-Neto V, Virolle T, Chneiweiss H, and Junier MP
- Subjects
- Aged, Animals, Brain metabolism, Brain pathology, Brain surgery, Brain Neoplasms pathology, Brain Neoplasms surgery, Carcinogenesis pathology, Cell Death physiology, Cell Proliferation physiology, Child, Child, Preschool, Female, Glioma pathology, Glioma surgery, Humans, Male, Mice, Nude, Middle Aged, Neoplasm Transplantation, Neoplastic Stem Cells pathology, Succinate-Semialdehyde Dehydrogenase metabolism, Brain Neoplasms metabolism, Carcinogenesis metabolism, Glioma metabolism, Hydroxybutyrates metabolism, Neoplastic Stem Cells metabolism, gamma-Aminobutyric Acid metabolism
- Abstract
Cell populations with differing proliferative, stem-like and tumorigenic states co-exist in most tumors and especially malignant gliomas. Whether metabolic variations can drive this heterogeneity by controlling dynamic changes in cell states is unknown. Metabolite profiling of human adult glioblastoma stem-like cells upon loss of their tumorigenicity revealed a switch in the catabolism of the GABA neurotransmitter toward enhanced production and secretion of its by-product GHB (4-hydroxybutyrate). This switch was driven by succinic semialdehyde dehydrogenase (SSADH) downregulation. Enhancing GHB levels via SSADH downregulation or GHB supplementation triggered cell conversion into a less aggressive phenotypic state. GHB affected adult glioblastoma cells with varying molecular profiles, along with cells from pediatric pontine gliomas. In all cell types, GHB acted by inhibiting α-ketoglutarate-dependent Ten-eleven Translocations (TET) activity, resulting in decreased levels of the 5-hydroxymethylcytosine epigenetic mark. In patients, low SSADH expression was correlated with high GHB/α-ketoglutarate ratios, and distinguished weakly proliferative/differentiated glioblastoma territories from proliferative/non-differentiated territories. Our findings support an active participation of metabolic variations in the genesis of tumor heterogeneity.
- Published
- 2017
- Full Text
- View/download PDF
47. Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors.
- Author
-
Rosenberg S, Verreault M, Schmitt C, Guegan J, Guehennec J, Levasseur C, Marie Y, Bielle F, Mokhtari K, Hoang-Xuan K, Ligon K, Sanson M, Delattre JY, and Idbaih A
- Subjects
- Aged, Brain Neoplasms pathology, Female, Gene Expression Profiling, Glioblastoma pathology, High-Throughput Nucleotide Sequencing methods, Humans, Male, Middle Aged, RNA, Messenger genetics, Real-Time Polymerase Chain Reaction, Reverse Transcriptase Polymerase Chain Reaction, Tumor Cells, Cultured, Biomarkers, Tumor genetics, Brain Neoplasms genetics, DNA Copy Number Variations genetics, Exome genetics, Glioblastoma genetics, Point Mutation genetics, Polymorphism, Single Nucleotide genetics
- Abstract
Background: Glioblastoma (GBM) is the deadliest primary brain cancer in adults. Emerging innovative therapies hold promise for personalized cancer treatment. Improving therapeutic options depends on research relying on relevant preclinical models. In this line we have established in the setting of the GlioTex project (GBM and Experimental Therapeutics) a GBM patient-derived cell line (GBM-PDCL) library. A multi-omic approach was used to determine the molecular landscape of PDCL and the extent to which they represent GBM tumors., Methods: Single nucleotide polymorphism array, expression arrays, exome sequencing, and RNA sequencing were used to measure and compare the molecular landscapes of 20 samples representing 10 human GBM tumors and paired GBM-PDCLs., Results: Copy number variations were similar for a median of 85% of the genome and for 59% of the major focal events. Somatic point mutations were similar in a median of 41%. Mutations in GBM driver and "druggable" genes were maintained in 67% of events. Mutations that were not conserved in the PDCL were mainly low allelic fraction and/or non-driver mutations. Based on RNA expression profiling, PDCLs cluster closely to their parental tumor with overexpression of pathways associated with cancer progression in PDCL., Conclusions: Overall, PDCLs recapitulate pivotal molecular alterations of paired-parental tumors supporting their use as a preclinical model of GBM. However, some driver aberrations are lost or gained in the passage from tumor to PDCL. Our results support using PDCL as a relevant preclinical model of GBM. Further investigations of changes between PDCLs and their parental tumor may provide insights into GBM biology., (© The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2017
- Full Text
- View/download PDF
48. UGT2B17 Expedites Progression of Castration-Resistant Prostate Cancers by Promoting Ligand-Independent AR Signaling.
- Author
-
Li H, Xie N, Chen R, Verreault M, Fazli L, Gleave ME, Barbier O, and Dong X
- Subjects
- Animals, Disease Progression, Humans, Ligands, Male, Mice, Mice, Nude, Receptors, Androgen metabolism, Signal Transduction, Tissue Array Analysis, Transfection, Glucuronosyltransferase metabolism, Minor Histocompatibility Antigens metabolism, Prostatic Neoplasms, Castration-Resistant genetics
- Abstract
Castration-resistant prostate cancer (CRPC) is characterized by a shift in androgen receptor (AR) signaling from androgen-dependent to androgen (ligand)-independent. UDP-glucuronosyltransferase 2B17 (UGT2B17) is a key enzyme that maintains androgen homeostasis by catabolizing AR agonists into inactive forms. Although enhanced UGT2B17 expression by antiandrogens has been reported in androgen-dependent prostate cancer, its roles in regulating AR signaling transformation and CRPC progression remain unknown. In this study, we show that higher UGT2B17 protein expression in prostate tumors is associated with higher Gleason score, metastasis, and CRPC progression. UGT2B17 expression and activity were higher in androgen-independent compared to androgen-dependent cell lines. UGT2B17 stimulated cancer cell proliferation, invasion, and xenograft progression to CRPC after prolonged androgen deprivation. Gene microarray analysis indicated that UGT2B17 suppressed androgen-dependent AR transcriptional activity and enhanced of ligand-independent transcriptional activity at genes associated with cell mitosis. These UGT2B17 actions were mainly mediated by activation of the c-Src kinase. In CRPC tumors, UGT2B17 expression was associated positively with c-Src activation. These results indicate that UGT2B17 expedites CRPC progression by enhancing ligand-independent AR signaling to activate cell mitosis in cancer cells. Cancer Res; 76(22); 6701-11. ©2016 AACR., (©2016 American Association for Cancer Research.)
- Published
- 2016
- Full Text
- View/download PDF
49. Blood-brain barrier, cytotoxic chemotherapies and glioblastoma.
- Author
-
Dréan A, Goldwirt L, Verreault M, Canney M, Schmitt C, Guehennec J, Delattre JY, Carpentier A, and Idbaih A
- Subjects
- Brain Neoplasms physiopathology, Glioblastoma physiopathology, Humans, Neoplasm Recurrence, Local, Antineoplastic Agents therapeutic use, Blood-Brain Barrier, Brain Neoplasms drug therapy, Glioblastoma drug therapy
- Abstract
Introduction: Glioblastomas (GBM) are the most common and aggressive primary malignant brain tumors in adults. The blood brain barrier (BBB) is a major limitation reducing efficacy of anti-cancer drugs in the treatment of GBM patients. Areas covered: Virtually all GBM recur after the first-line treatment, at least partly, due to invasive tumor cells protected from chemotherapeutic agents by the intact BBB in the brain adjacent to tumor. The passage through the BBB, taken by antitumor drugs, is poorly and heterogeneously documented in the literature. In this review, we have focused our attention on: (i) the BBB, (ii) the passage of chemotherapeutic agents across the BBB and (iii) the strategies investigated to overcome this barrier. Expert commentary: A better preclinical knowledge of the crossing of the BBB by antitumor drugs will allow optimizing their clinical development, alone or combined with BBB bypassing strategies, towards an increased success rate of clinical trials.
- Published
- 2016
- Full Text
- View/download PDF
50. Selective and sensitive quantification of the cytochrome P450 3A4 protein in human liver homogenates through multiple reaction monitoring mass spectrometry.
- Author
-
Cieślak A, Kelly I, Trottier J, Verreault M, Wunsch E, Milkiewicz P, Poirier G, Droit A, and Barbier O
- Subjects
- Cytochrome P-450 CYP3A classification, Cytochrome P-450 Enzyme System genetics, Humans, Liver injuries, Liver metabolism, Microsomes, Liver metabolism, Tandem Mass Spectrometry, Cytochrome P-450 CYP3A genetics, Microsomes, Liver chemistry, Proteomics
- Abstract
This study aimed at establishing a sensitive multiple reaction monitoring-mass spectrometry (MRM-MS) method for the quantification of the drug metabolizing cytochrome P450 (CYP)3A4 enzyme in human liver homogenates. Liver samples were subjected to trypsin digestion. MRM-MS analyses were performed using three transitions optimized on one purified synthetic peptide unique to CYP3A4 and the standardizing protein, calnexin. Coefficient of variations for the precision and reproducibility of the MRM-MS measurement were also determined. The method was applied to liver samples from ten non-cholestatic donors and 34 cholestatic patients with primary biliary cholangitis (n = 12; PBC), primary sclerosing cholangitis (n = 10; PSC) or alcoholic liver disease (n = 12; ALD). The established method presented high sensitivity with limit of detection lower than 5 fmol, and was successfully applied for the absolute and relative quantification of CYP3A4 in both whole liver homogenate and microsomal fractions. When all groups were analyzed together, a significant correlation was observed for the MRM-based CYP3A4 protein quantification in homogenates and microsomes (r = 0.49, p < 0.001). No statistically significant difference was detected between CYP3A4 levels in PSC, PBC, ALD and control samples. Finally, the MRM-MS quantification of CYP3A4 in homogenates also correlated (r = 0.44; p < 0.05) with the level of enzyme activity in the same samples, as determined by measuring the chenodeoxycholic to hyocholic acid conversion. The established method provides a sensitive tool to evaluate the CYP3A4 protein in human liver homogenates from patients with normal or chronic/severe hepatic injury., (© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.)
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.